Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.2K

Dasatinib Inhibits Basal B Breast Cancer Through ETS1-Mediated Extracellular Matrix Remodeling

Xinyu Guo1,2, Heng Sun1,2,3, Feng Yu4

  • 1Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, China.

Biomedicines
|December 30, 2025
PubMed

Insights

Dasatinib shows promise in treating aggressive triple-negative breast cancer (TNBC), especially the basal B subtype. This drug inhibits cancer cell migration and invasion by targeting ETS proto-oncogene 1 (ETS1) and matrix metalloproteinase-3 (MMP3).

Area of Science:

  • Oncology
  • Drug Discovery
  • Cancer Metastasis

Background:

  • Triple-negative breast cancer (TNBC), particularly basal B type, is highly invasive and metastatic.
  • Effective therapies for metastatic TNBC are urgently needed.
  • Understanding TNBC's underlying mechanisms is crucial for developing targeted treatments.

Purpose of the Study:

  • To identify effective therapeutic drugs for metastatic TNBC through drug repurposing.
  • To elucidate the mechanisms by which potential drugs inhibit TNBC invasion and metastasis.
  • To evaluate dasatinib as a therapeutic agent for aggressive TNBC.

Main Methods:

  • Systematic screening of 140 FDA-approved drugs using live-cell imaging wound-healing assays.
  • Validation of drug efficacy through in vitro invasion assays, in vivo models, and ex vivo organoid cultures.
  • Analysis of dasatinib's molecular mechanisms, including effects on the actin cytoskeleton, ETS1, and MMP3 expression.

Main Results:

  • Dasatinib demonstrated significant anti-cancer activity in aggressive TNBC, especially basal B type with high ETS proto-oncogene 1 (ETS1) expression.
  • Dasatinib disrupts the actin cytoskeleton, reduces cell motility, and suppresses ETS1 and matrix metalloproteinase-3 (MMP3) expression, inhibiting invasion.
  • A combination therapy of dasatinib with an anti-programmed cell death protein-1 (PD-1) antibody showed potential.

Conclusions:

  • Dasatinib is a potential therapeutic option for metastatic TNBC.
  • Targeting patients with high ETS1 expression may optimize dasatinib treatment response.
  • Further research into combination therapies, including with PD-1 inhibitors, is warranted.
Keywords:
ETS proto-oncogene 1 (ETS1)dasatinibextracellular matrixmatrix metalloproteinase-3 (MMP3)metastasistriple-negative breast cancer (TNBC)

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.1K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K